Adagrasib (MRTX849): Mechanism of Action

Adagrasib (MRTX849) MOA:Targeting KRAS G12C/MAPK Pathway for Non-Small Cell Lung Cancer

🎯 check Adagrasib (MRTX849) product page

Adagrasib (MRTX849) is a potent, selective, and covalent KRAS G12C inhibitor. It affects the KRAS/MAPK/ERK signaling pathways by covalently binding to the mutant KRAS protein at Cys12, effectively inhibiting KRAS-dependent signal transduction and suppressing cancer cell viability and proliferation.

Primary Applications and Mechanism of Action